Herantis Pharma Oyj Stock Nasdaq Helsinki
Equities
FI4000087861
Biotechnology & Medical Research
Sales 2024 * | 1.3M 1.39M | Sales 2025 * | - | Capitalization | 29.43M 31.47M |
---|---|---|---|---|---|
Net income 2024 * | -3M -3.21M | Net income 2025 * | -4M -4.28M | EV / Sales 2024 * | 19.4 x |
Net cash position 2024 * | 4.2M 4.49M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.93% |
Latest transcript on Herantis Pharma Oyj
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 07-12-31 | |
Antti Vuolanto
CEO | Chief Executive Officer | - | 18-02-11 |
Tone Kvåle
DFI | Director of Finance/CFO | 55 | 20-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 13-12-31 | |
Director/Board Member | 53 | 20-03-10 | |
Chairman | 64 | 11-12-31 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |